BridgeBio Pharma (NASDAQ:BBIO) Director Sells 2,808 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Hannah Valantine sold 2,808 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $68.00, for a total transaction of $190,944.00. Following the completion of the sale, the director directly owned 11,455 shares of the company’s stock, valued at $778,940. The trade was a 19.69% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hannah Valantine also recently made the following trade(s):

• On Tuesday, June 23rd, Hannah Valantine sold 2,196 shares of BridgeBio Pharma stock. The stock was sold at an average price of $68.57, for a total transaction of $150,579.72.

BridgeBio Pharma Trading Up 0.9%

Shares of BBIO stock traded up $0.63 on Wednesday, hitting $69.26. The stock had a trading volume of 4,190,473 shares, compared to its average volume of 2,788,713. BridgeBio Pharma, Inc. has a twelve month low of $41.80 and a twelve month high of $84.94. The company has a fifty day moving average price of $69.37 and a two-hundred day moving average price of $71.90. The firm has a market cap of $13.56 billion, a P/E ratio of -18.52 and a beta of 0.97.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The company had revenue of $194.51 million during the quarter, compared to analyst estimates of $178.07 million. The company’s revenue for the quarter was up 66.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.88) earnings per share. On average, analysts expect that BridgeBio Pharma, Inc. will post -2.29 earnings per share for the current year.

Analysts Set New Price Targets

BBIO has been the topic of several recent analyst reports. Royal Bank Of Canada assumed coverage on BridgeBio Pharma in a report on Thursday, April 9th. They set an “outperform” rating and a $100.00 price objective on the stock. Canaccord Genuity Group began coverage on shares of BridgeBio Pharma in a report on Wednesday, June 3rd. They set a “buy” rating and a $104.00 target price on the stock. Citigroup assumed coverage on shares of BridgeBio Pharma in a report on Tuesday, May 19th. They issued a “neutral” rating and a $82.00 price target for the company. Barclays reissued an “overweight” rating on shares of BridgeBio Pharma in a research report on Tuesday, March 10th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of BridgeBio Pharma in a research report on Friday, May 15th. Twenty-two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $91.05.

Institutional Trading of BridgeBio Pharma

Institutional investors have recently made changes to their positions in the business. Brooklands Fund Management Ltd acquired a new position in BridgeBio Pharma during the fourth quarter worth $210,348,000. Price T Rowe Associates Inc. MD lifted its position in BridgeBio Pharma by 144.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,828,746 shares of the company’s stock worth $292,862,000 after buying an additional 2,261,181 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of BridgeBio Pharma by 25.8% during the 4th quarter. Janus Henderson Group PLC now owns 11,000,457 shares of the company’s stock worth $841,349,000 after buying an additional 2,259,378 shares during the last quarter. Norges Bank acquired a new position in shares of BridgeBio Pharma during the 4th quarter worth about $116,802,000. Finally, Wellington Management Group LLP grew its holdings in shares of BridgeBio Pharma by 130.4% in the 4th quarter. Wellington Management Group LLP now owns 2,348,731 shares of the company’s stock valued at $179,654,000 after acquiring an additional 1,329,537 shares in the last quarter. Institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.